DE3752364T2 - Osteoinduktive Zusammensetzungen - Google Patents
Osteoinduktive Zusammensetzungen Download PDFInfo
- Publication number
- DE3752364T2 DE3752364T2 DE3752364T DE3752364T DE3752364T2 DE 3752364 T2 DE3752364 T2 DE 3752364T2 DE 3752364 T DE3752364 T DE 3752364T DE 3752364 T DE3752364 T DE 3752364T DE 3752364 T2 DE3752364 T2 DE 3752364T2
- Authority
- DE
- Germany
- Prior art keywords
- bone
- protein
- dna sequence
- cell
- bmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002138 osteoinductive effect Effects 0.000 title description 8
- 239000000203 mixture Substances 0.000 title description 7
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 36
- 230000007547 defect Effects 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000011164 ossification Effects 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims description 9
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 210000000845 cartilage Anatomy 0.000 claims description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 7
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 230000022159 cartilage development Effects 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 4
- 101000762376 Bos taurus Bone morphogenetic protein 3 Proteins 0.000 claims 2
- 238000009395 breeding Methods 0.000 claims 2
- 230000001488 breeding effect Effects 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 21
- 230000008569 process Effects 0.000 abstract description 9
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000003239 periodontal effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 50
- 239000000523 sample Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 230000008468 bone growth Effects 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 239000003102 growth factor Substances 0.000 description 17
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 239000004202 carbamide Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 6
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000002188 osteogenic effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000001155 isoelectric focusing Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010004250 Inhibins Proteins 0.000 description 2
- 102000002746 Inhibins Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical group C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 101001059240 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Site-specific recombinase Flp Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- XFWJKVMFIVXPKK-UHFFFAOYSA-N calcium;oxido(oxo)alumane Chemical compound [Ca+2].[O-][Al]=O.[O-][Al]=O XFWJKVMFIVXPKK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045888 human BMP3 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Photoreceptors In Electrophotography (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88077686A | 1986-07-01 | 1986-07-01 | |
| US880776 | 1986-07-01 | ||
| US94333286A | 1986-12-17 | 1986-12-17 | |
| US943332 | 1986-12-17 | ||
| US2828587A | 1987-03-20 | 1987-03-20 | |
| US28285 | 1987-03-20 | ||
| US31346 | 1987-03-26 | ||
| US07/031,346 US4877864A (en) | 1987-03-26 | 1987-03-26 | Osteoinductive factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3752364D1 DE3752364D1 (de) | 2003-04-24 |
| DE3752364T2 true DE3752364T2 (de) | 2004-03-04 |
Family
ID=27487661
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3752364T Expired - Lifetime DE3752364T2 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive Zusammensetzungen |
| DE2003199007 Active DE10399007I2 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive Mittel |
| DE3752393T Expired - Lifetime DE3752393D1 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive Zusammensetzungen |
| DE3751887T Expired - Lifetime DE3751887T2 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive mittel |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2003199007 Active DE10399007I2 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive Mittel |
| DE3752393T Expired - Lifetime DE3752393D1 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive Zusammensetzungen |
| DE3751887T Expired - Lifetime DE3751887T2 (de) | 1986-07-01 | 1987-06-30 | Osteoinduktive mittel |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP1254956B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2713715B2 (cg-RX-API-DMAC7.html) |
| AT (3) | ATE419349T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU613314B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1341212C (cg-RX-API-DMAC7.html) |
| DE (4) | DE3752364T2 (cg-RX-API-DMAC7.html) |
| DK (2) | DK172275B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2007625A6 (cg-RX-API-DMAC7.html) |
| GR (1) | GR871028B (cg-RX-API-DMAC7.html) |
| IE (1) | IE75881B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL83003A (cg-RX-API-DMAC7.html) |
| LU (1) | LU91005I2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX170919B (cg-RX-API-DMAC7.html) |
| MY (1) | MY102505A (cg-RX-API-DMAC7.html) |
| NL (1) | NL300116I2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ220894A (cg-RX-API-DMAC7.html) |
| PT (1) | PT85225B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1988000205A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US6020313A (en) * | 1987-10-09 | 2000-02-01 | University Of Kansas | Method for inducing bone formation using an extract of human osteosarcoma cell line SAOS-2 |
| US5035901A (en) * | 1987-10-09 | 1991-07-30 | University Of Kansas | Bone inducing agent from a human osteosarcoma cell line |
| US5258494A (en) * | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
| US5162114A (en) * | 1989-02-23 | 1992-11-10 | Stryker Corporation | Bone collagen matrix for xenogenic implants |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US5108753A (en) * | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
| US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5324819A (en) * | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
| US5250302A (en) * | 1988-04-08 | 1993-10-05 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US4968590A (en) * | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
| US5670336A (en) * | 1988-04-08 | 1997-09-23 | Stryker Corporation | Method for recombinant production of osteogenic protein |
| EP0723013B1 (en) * | 1988-04-08 | 2003-06-18 | Stryker Corporation | Biosynthetic osteogenic proteins and osteogenic devices containing them |
| US5354557A (en) * | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US5344654A (en) * | 1988-04-08 | 1994-09-06 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
| KR900700617A (ko) * | 1988-04-08 | 1990-08-16 | 브루스 엠. 에이센 | 뼈 및 연골 유도 조성물 |
| US5284756A (en) * | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
| US5106626A (en) * | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US4915301A (en) * | 1988-11-15 | 1990-04-10 | International Flavors & Fragrances, Inc. | Container with sorbent member and microporous membrane for dispensing vapor from volatile liquid |
| CA2030518C (en) * | 1989-03-28 | 2000-03-21 | Elizabeth A. Wang | Osteoinductive compositions |
| JP3504259B2 (ja) | 1989-03-28 | 2004-03-08 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | 骨誘導組成物 |
| PT94241A (pt) * | 1989-06-02 | 1991-02-08 | Chiron Corp | Processo para a preparacao de factor calcificacao ossea e de composicoes farmaceuticas que os contem |
| CA2020729A1 (en) * | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
| WO1991002744A1 (en) * | 1989-08-21 | 1991-03-07 | Celtrix Laboratories, Inc. | Bone-specific protein |
| ATE140965T1 (de) * | 1989-09-06 | 1996-08-15 | Takeda Chemical Industries Ltd | Protein, dna und ihre verwendung |
| JP2845346B2 (ja) * | 1989-10-17 | 1999-01-13 | ストライカー・コーポレーション | 骨形成具 |
| US5168050A (en) * | 1990-05-24 | 1992-12-01 | Genentech, Inc. | Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion |
| US5645591A (en) * | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| US5364839A (en) * | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| ATE253589T1 (de) * | 1990-09-26 | 2003-11-15 | Inst Genetics Llc | Bmp-5-derivate |
| US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| US5674844A (en) * | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US5972884A (en) * | 1991-03-11 | 1999-10-26 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
| US5656593A (en) * | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5739107A (en) * | 1991-03-11 | 1998-04-14 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
| US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
| CA2363965C (en) | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US6090776A (en) * | 1991-03-11 | 2000-07-18 | Creative Bio Molecules, Inc. | Morphogen treatment of organ implants |
| US5652118A (en) * | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | Nucleic acid encoding a novel morphogenic protein, OP-3 |
| US5652337A (en) * | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | OP-3-induced morphogenesis |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US7056882B2 (en) | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
| US5318898A (en) * | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| CA2102808A1 (en) | 1991-05-10 | 1992-11-11 | Hanne Bentz | Targeted delivery of bone growth factors |
| KR0145278B1 (ko) * | 1991-06-21 | 1998-07-15 | 브루스 엠. 에이센 | 골형성원 단백질 약제 |
| US6022853A (en) * | 1991-08-30 | 2000-02-08 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
| US5270300A (en) * | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| CA2129820C (en) * | 1992-02-12 | 2003-06-17 | Helge Neidhardt | Dna sequences encoding novel growth/differentiation factors |
| IL106278A0 (en) * | 1992-07-13 | 1993-11-15 | Sumitomo Metal Ind | Bone formation-inducing protein |
| CA2144513C (en) * | 1992-09-15 | 1998-12-15 | Thangavel Kuberasampath | Morphogen-induced periodontal tissue regeneration |
| DE69325913T2 (de) * | 1992-09-15 | 2001-05-17 | Creative Biomolecules, Inc. | Durch morphogen induzierte periodontolgeweberegeneration |
| ES2213745T3 (es) * | 1993-05-12 | 2004-09-01 | Genetics Institute, Llc | Composiciones de bmp-11. |
| US6333168B1 (en) * | 1993-05-20 | 2001-12-25 | The Trustees Of Columbia University In The City Of New York | Cloning, expression and uses of dorsalin-1 |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| ES2255059T3 (es) | 1993-12-07 | 2006-06-16 | Genetics Institute, Llc | Bmp-12, bmp-13 y composiciones suyas inductoras de tendon. |
| US5906827A (en) † | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| ES2203701T3 (es) * | 1995-06-05 | 2004-04-16 | Genetics Institute, Llc | Uso de proteinas morfogenicas de hueso para sanar y reparar uniones de tejido conjuntivo. |
| CN1198775A (zh) | 1995-08-08 | 1998-11-11 | 托马斯杰弗逊大学 | 重组c－蛋白酶及其加工、方法和用途 |
| US5807981A (en) * | 1995-12-13 | 1998-09-15 | Fibrogen Inc. | Peptides which are cleaved by C-proteinase |
| ES2201287T5 (es) | 1996-03-22 | 2007-10-16 | Curis, Inc. | Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central. |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| JP2001509010A (ja) * | 1996-11-22 | 2001-07-10 | アクゾ・ノベル・エヌ・ベー | Ｂｍｐ―４プロモーターならびに骨粗鬆症の予防および／または治療用の治療剤のスクリーニングにおけるその用途 |
| AU6267798A (en) * | 1997-02-07 | 1998-08-26 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
| US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| ATE278414T1 (de) | 1997-05-05 | 2004-10-15 | Curis Inc | Therapien zur behandlung von akutem nierenversagen |
| AU742663B2 (en) | 1997-05-30 | 2002-01-10 | Stryker Corporation | Methods for evaluating tissue morphogenesis and activity |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| PT2016951E (pt) | 1998-03-17 | 2012-09-27 | Genentech Inc | Polipéptidos homólogos de vegf e de bmp1 |
| US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
| US6258778B1 (en) | 1998-07-13 | 2001-07-10 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
| US6916783B2 (en) | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
| US6958149B2 (en) | 1998-10-06 | 2005-10-25 | Stryker Corporation | Repair of larynx, trachea, and other fibrocartilaginous tissues |
| WO2000020559A1 (en) | 1998-10-06 | 2000-04-13 | Rush-Presbyterian-St. Luke's Medical Center | Method for the treatment of chemonucleolysis |
| US7572440B2 (en) | 1999-07-30 | 2009-08-11 | Stryker Corporation | Method for repairing a defect in an intervertebral disc |
| JP3786533B2 (ja) | 1998-11-12 | 2006-06-14 | 善彦 西村 | ペプチド及び骨形成促進剤 |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| EP1148897B1 (en) * | 1999-02-01 | 2003-12-10 | Genetics Institute, LLC | Methods and compositions for healing and repair of articular cartilage |
| DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
| AU771546B2 (en) * | 1999-09-01 | 2004-03-25 | Ppd Development, Lp | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2001016323A2 (en) * | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| AU6865100A (en) * | 1999-09-02 | 2001-04-10 | Mitsubishi Pharma Corporation | Osteogenesis promoting agents |
| ATE271886T1 (de) | 1999-10-15 | 2004-08-15 | Inst Genetics Llc | Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine |
| WO2002053592A1 (en) | 2000-12-28 | 2002-07-11 | Shionogi & Co., Ltd. | Novel polypeptide and dna thereof |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| DE60226321T2 (de) | 2001-06-01 | 2009-07-09 | Wyeth | Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| US7160725B2 (en) | 2001-11-13 | 2007-01-09 | Curis, Inc. | Hedgehog signaling promotes the formation of three dimensional cartilage matrices |
| AU2002308204B9 (en) | 2001-11-19 | 2008-06-12 | Scil Technology Gmbh | Device having osteoinductive and osteoconductive properties |
| US7160994B2 (en) | 2002-03-28 | 2007-01-09 | Trustees Of The University Of Pennsylvania | Osteoclast-specific genes and proteins and uses thereof |
| US8067557B2 (en) | 2002-03-28 | 2011-11-29 | The Trustees Of The University Of Pennsylvania | OCL-2A3 compositions and uses thereof |
| WO2004024199A1 (en) | 2002-09-10 | 2004-03-25 | Scil Technology Gmbh | Metal implant coated under reduced oxygen concentration with osteoinductive protein |
| EP1675608B1 (en) | 2003-09-12 | 2007-03-21 | Wyeth | Injectable calcium phosphate solid rods for delivery of osteogenic proteins |
| US8734525B2 (en) | 2003-12-31 | 2014-05-27 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| EP1701729B1 (en) | 2003-12-31 | 2018-05-02 | Warsaw Orthopedic, Inc. | Improved bone matrix compositions and methods |
| EP1571159A1 (en) * | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| WO2005089829A2 (en) | 2004-03-10 | 2005-09-29 | Scil Technology Gmbh | Coated implants, their manufacturing and use thereof |
| EP1763362B1 (en) | 2004-05-25 | 2011-07-06 | Stryker Corporation | Use of op-1 for treating cartilage defects |
| US8506646B2 (en) | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
| WO2007053850A2 (en) | 2005-11-01 | 2007-05-10 | Osteotech, Inc. | Bone matrix compositions and methods |
| US20090298761A1 (en) | 2006-05-17 | 2009-12-03 | Donald Engelman | Methods of treating cartilage defects using a soluble morphogenic protein complex |
| KR20090105913A (ko) | 2006-11-02 | 2009-10-07 | 다니엘 제이 카폰 | 이동 부분을 갖는 하이브리드 면역글로불린 |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
| US9554920B2 (en) | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
| CA2690457C (en) | 2007-06-15 | 2018-02-20 | Osteotech, Inc. | Bone matrix compositions and methods |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| US9358113B2 (en) | 2007-07-10 | 2016-06-07 | Warsaw Orthopedic, Inc. | Delivery system |
| CA2695697A1 (en) | 2007-08-07 | 2009-02-12 | Advanced Technologies And Regenerative Medicine, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
| JP2011514331A (ja) | 2008-02-13 | 2011-05-06 | キース フルスカ， | 血管硬化症の治療における使用のためのｂｍｐ−７ |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| EP2396025A2 (en) | 2009-02-12 | 2011-12-21 | Stryker Corporation | Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease |
| WO2010093959A2 (en) | 2009-02-12 | 2010-08-19 | Osteotech, Inc. | Delivery systems, tools, and methods of use |
| SG173634A1 (en) | 2009-02-12 | 2011-09-29 | Stryker Corp | COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS |
| US8828937B2 (en) * | 2009-03-12 | 2014-09-09 | Haase Investments Ug | Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity |
| WO2010110974A1 (en) | 2009-03-24 | 2010-09-30 | Stryker Corporation | Methods and compositions for tissue engineering |
| WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| SG177467A1 (en) * | 2009-07-23 | 2012-02-28 | Agency Science Tech & Res | Pre-natal mesenchymal stem cells |
| US20110224138A1 (en) | 2009-09-09 | 2011-09-15 | Julie Krop | Methods for treating pain induced by injuries and diseases of an articular joint |
| EP2352750B1 (en) | 2009-09-17 | 2012-06-13 | Stryker Corporation | Buffers for controlling the ph of bone morphogenetic proteins |
| EP2516456A1 (en) | 2009-12-22 | 2012-10-31 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| EP3562839A4 (en) | 2016-12-30 | 2020-09-02 | Biogend Therapeutics Co., Ltd. | RECOMBINANT POLYPEPTIDES, ASSOCIATED COMPOSITIONS AND PROCESSES |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4619989A (en) * | 1981-05-05 | 1986-10-28 | The Regents Of The University Of Cal. | Bone morphogenetic protein composition |
| US4455256A (en) * | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4434094A (en) * | 1983-04-12 | 1984-02-28 | Collagen Corporation | Partially purified osteogenic factor and process for preparing same from demineralized bone |
| US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| EP0128041A3 (en) * | 1983-06-06 | 1986-12-03 | David Jeston Baylink | Polypeptides exhibiting skeletal growth factor activity |
| US4795804A (en) * | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| US4608199A (en) * | 1984-03-20 | 1986-08-26 | Arnold Caplan | Bone protein purification process |
| AU599572B2 (en) | 1984-07-06 | 1990-07-26 | Novartis Ag | Lymphokine production and purification |
| ATE128715T1 (de) | 1984-07-16 | 1995-10-15 | Celtrix Pharma | Polypeptide induzierende faktoren in knochen und knorpel. |
| ATE78515T1 (de) | 1984-10-05 | 1992-08-15 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| US4563350A (en) * | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
-
1987
- 1987-06-26 IL IL8300387A patent/IL83003A/en not_active IP Right Cessation
- 1987-06-29 IE IE173987A patent/IE75881B1/en not_active IP Right Cessation
- 1987-06-30 DE DE3752364T patent/DE3752364T2/de not_active Expired - Lifetime
- 1987-06-30 EP EP02014841A patent/EP1254956B1/en not_active Expired - Lifetime
- 1987-06-30 AT AT02014841T patent/ATE419349T1/de not_active IP Right Cessation
- 1987-06-30 GR GR871028A patent/GR871028B/el unknown
- 1987-06-30 AT AT87905023T patent/ATE141928T1/de active
- 1987-06-30 NZ NZ220894A patent/NZ220894A/xx unknown
- 1987-06-30 CA CA000540928A patent/CA1341212C/en not_active Expired - Fee Related
- 1987-06-30 DE DE2003199007 patent/DE10399007I2/de active Active
- 1987-06-30 MY MYPI87000921A patent/MY102505A/en unknown
- 1987-06-30 EP EP95111771A patent/EP0688869B1/en not_active Expired - Lifetime
- 1987-06-30 AU AU77835/87A patent/AU613314B2/en not_active Expired
- 1987-06-30 ES ES8701909A patent/ES2007625A6/es not_active Expired
- 1987-06-30 DE DE3752393T patent/DE3752393D1/de not_active Expired - Lifetime
- 1987-06-30 AT AT95111771T patent/ATE234921T1/de not_active IP Right Cessation
- 1987-06-30 MX MX007140A patent/MX170919B/es unknown
- 1987-06-30 DE DE3751887T patent/DE3751887T2/de not_active Expired - Lifetime
- 1987-06-30 WO PCT/US1987/001537 patent/WO1988000205A1/en not_active Ceased
- 1987-06-30 EP EP87905023A patent/EP0313578B1/en not_active Expired - Lifetime
- 1987-06-30 JP JP62504617A patent/JP2713715B2/ja not_active Expired - Lifetime
- 1987-07-01 PT PT85225A patent/PT85225B/pt unknown
-
1988
- 1988-02-29 DK DK106288A patent/DK172275B1/da not_active IP Right Cessation
-
1993
- 1993-06-01 JP JP5130389A patent/JP2729222B2/ja not_active Expired - Lifetime
-
1997
- 1997-05-09 DK DK199700534A patent/DK172503B1/da not_active IP Right Cessation
- 1997-06-27 JP JP09171615A patent/JP3093682B2/ja not_active Expired - Lifetime
-
2003
- 2003-01-29 LU LU91005C patent/LU91005I2/fr unknown
- 2003-02-24 NL NL300116C patent/NL300116I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3752364T2 (de) | Osteoinduktive Zusammensetzungen | |
| DE69031939T2 (de) | Osteoinduktive zusammensetzungen | |
| DE69132823T2 (de) | Knochen- und knorpel-bildung hervorrufende proteine | |
| DE69228118T2 (de) | Bmp-9 zusammensetzungen | |
| DE69528058T2 (de) | Bmp-9 zusammensetzungen | |
| DE68927995T2 (de) | Osteogene faktoren | |
| US4877864A (en) | Osteoinductive factors | |
| DE69433742T2 (de) | Bmp-10 zusammensetzungen | |
| US5141905A (en) | Dna sequences encoding bmp-7 proteins | |
| DE68925773T2 (de) | Osteogene vorrichtungen | |
| US5459047A (en) | BMP-6 proteins | |
| US5618924A (en) | BMP-2 products | |
| DE69433530T2 (de) | Bmp-11 zusammensetzungen | |
| US6177406B1 (en) | BMP-3 products | |
| US5106748A (en) | Dna sequences encoding 5 proteins | |
| DE69434651T2 (de) | Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen | |
| DE69233022T2 (de) | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung | |
| US5187076A (en) | DNA sequences encoding BMP-6 proteins | |
| US5366875A (en) | Methods for producing BMP-7 proteins | |
| DE69133338T2 (de) | Bmp-5-derivate | |
| US5635373A (en) | Bone morphogenic protein-5(BMP-5) and DNA encoding same | |
| DE69129865T2 (de) | Osteogene peptide | |
| EP0713529A1 (de) | NEUER WACHSTUMS-/DIFFERENZIERUNGSFAKTOR DER TGF-$g(b)-FAMILIE | |
| DE69832880T2 (de) | Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen | |
| IE83704B1 (en) | Novel osteoinductive factors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |